CE-Mark paves the way for Spirecut's global market entry

Founded in 2020 with headquarters in Muttenz, Spirecut is a MedTech startup at the forefront of hand surgery. The startup commercializes non-invasive, ultrasound-guided instruments designed to address carpal tunnel syndrome and trigger finger – afflictions impacting approximately one in seven individuals globally. The device has been used to treat 30 patients during its clinical investigation and on 1200 patients over the past two years. A recent European study underscores the benefits. It demonstrates a remarkable recovery rate from carpal tunnel syndrome with Spirecut's methodology, allowing for an almost immediate return to daily activities post-procedure.

After the FDA approval in 2022, Spirecut has newly obtained the CE mark, which enables entry into targeted markets in 2024. Last year, the company secured exclusive distribution agreements with Curmed AG in Switzerland and Sovereign Medical Group in the UK, Ireland, USA, and Canada. These collaborations will facilitate smooth market launches in those countries.

"By choosing Switzerland, we are capitalizing on world-leading manufacturing expertise in Medtech and accessing a rich talent pool while benefiting from the effective Swiss innovation ecosystem," said Founder and CEO Prof. Frédéric Schuind, a distinguished hand surgery expert. "Spirecut's pioneering technology is set to transform the landscape of hand surgery, significantly reducing invasiveness and enabling patients to enjoy a dramatically quicker recovery period. We are witnessing a major shift towards ultrasound-guided surgery, enabling a wide range of non-invasive interventions. Spirecut is well-positioned to contribute to this transformative development within the healthcare sector," he added.